{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:22:32Z","timestamp":1762809752417,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:p>This case report highlights the management of recurrent urinary tract infections (UTIs) caused by multidrug-resistant (MDR) <jats:italic>Pseudomonas aeruginosa<\/jats:italic> in a post-renal transplant patient. Despite the challenges posed by antibiotic resistance, the patient was successfully treated with an extended infusion of meropenem, underscoring the efficacy of this approach in such difficult cases. The patient's recurrent infections required multiple hospitalizations and adjustments in treatment protocols, including the use of alternative antibiotics like fosfomycin and tailored immunosuppressive management to control both infection and rejection. This case is noteworthy for demonstrating the successful management of recurrent UTIs in the immunocompromised patient population, providing valuable insights into the treatment strategies that can be employed in similar clinical scenarios.<\/jats:p>","DOI":"10.3389\/frtra.2025.1500066","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T11:16:38Z","timestamp":1752491798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Persistent drug-resistant Pseudomonas aeruginosa infection in a young post-kidney transplant patient that proved fatal"],"prefix":"10.3389","volume":"4","author":[{"given":"Supreeta R.","family":"Shettar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahadevaiah Neelambike","family":"Sumana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjunath S.","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogeesh D.","family":"Maheshwarappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghukanth G","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamshi P","family":"Dharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Kalyatanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. K.","family":"Megha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0940-2993(01)80009-9","article-title":"CL Berry transplantation pathology a guide for practicing pathologists 1999 Springer Verlag New York and London 222 pages with 94 figures and 31 tables","volume":"52","author":"Katenkamp","year":"2001","journal-title":"Exp Toxicol Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.transproceed.2008.05.065","article-title":"Infective complications in renal allograft recipients: epidemiology and outcome","volume":"40","author":"Veroux","year":"2008","journal-title":"Transplant Proc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/320897","article-title":"Epidemiology of infections after solid-organ transplantation","volume":"33","author":"Snydman","year":"2001","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/ajt.12124","article-title":"AST infectious diseases community of practice. Urinary tract infections in solid organ transplantation","volume":"13","author":"Parasuraman","year":"2013","journal-title":"Am J Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1016\/j.transproceed.2014.10.033","article-title":"Blood stream infections in renal transplant recipients: a single-center study","volume":"46","author":"Daskalaki","year":"2014","journal-title":"Transplant Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1399-3062.2011.00671.x","article-title":"Microbial ureteral stent colonization in renal transplant recipients: frequency and influence on the short-time functional outcome","volume":"14","author":"Bonkat","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.transproceed.2015.03.046","article-title":"Bacterial infections in renal transplant recipients","volume":"47","author":"Adamska","year":"2015","journal-title":"Transplant Proc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.transproceed.2011.07.010","article-title":"Urinary tract infections in renal transplant recipients","volume":"43","author":"Go\u0142\u0119biewska","year":"2011","journal-title":"Transplant Proc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4103\/1319-2442.390256","article-title":"Recurrent urinary tract infections in renal transplant recipients: risk factors and outcomes in low-resource settings","volume":"33","author":"Jamil","year":"2022","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/antibiotics11050579","article-title":"New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review","volume":"11","author":"Losito","year":"2022","journal-title":"Antibiotics"},{"key":"B11","article-title":"tWHO publishes the list of bacteria for which new antibiotics are urgently needed","year":"2017"},{"key":"B12","article-title":"Multidrug-resistant Pseudomonas aeruginosa | A.R. & Patient Safety Portal","year":"2019"},{"key":"B13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/cells12010199","article-title":"Pseudomonas aeruginosa: infections, animal modeling, and therapeutics","volume":"12","author":"Wood","year":"2023","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/ph16091230","article-title":"Age of antibiotic resistance in MDR\/XDR clinical pathogen of Pseudomonas aeruginosa","volume":"16","author":"Kothari","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.2147\/IDR.S185753","article-title":"Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study","volume":"11","author":"Gomila","year":"2018","journal-title":"Infect Drug Resist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B20","volume-title":"Treatment Guidelines for Antimicrobial Use in Common Syndromes","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1099\/jmm.0.000214","article-title":"Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications","volume":"65","author":"Tsala","year":"2016","journal-title":"J Med Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/antibiotics12121653","article-title":"Intravenous fosfomycin for systemic multidrug-resistant pseudomonas aeruginosa infections","volume":"12","author":"Pipitone","year":"2023","journal-title":"Antibiotics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jgar.2023.03.010","article-title":"Real-life experience with IV fosfomycin in Canada: results from the Canadian LEadership on antimicrobial real-life usage (CLEAR) registry","volume":"33","author":"Zhanel","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/antibiotics11101432","article-title":"Antimicrobial treatment of Pseudomonas aeruginosa severe sepsis","volume":"11","author":"Zakhour","year":"2022","journal-title":"Antibiotics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40121-021-00551-2","article-title":"Does prolonged infusion time really improve the efficacy of meropenem therapy? A prospective study in critically ill patients","volume":"11","author":"Zhao","year":"2022","journal-title":"Infect Dis Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.06389-11","article-title":"Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock","volume":"56","author":"Taccone","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2025.1500066\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T11:16:39Z","timestamp":1752491799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2025.1500066\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":27,"alternative-id":["10.3389\/frtra.2025.1500066"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2025.1500066","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"article-number":"1500066"}}